When was Samsung Bioepis founded?

Samsung Bioepis was founded in 2012.

Where is Samsung Bioepis located?

Samsung Bioepis is headquartered in Incheon, South Korea.

How many employees does Samsung Bioepis have?

As of Mar 31, 2026, the latest employee count at Samsung Bioepis is 1586.

Is Samsung Bioepis a funded company?

Samsung Bioepis is a funded company, having raised a total of $***** in its 1st and only funding round.

How much is Samsung Bioepis worth?

The last known valuation of Samsung Bioepis was $***** as of Jan 27, 2022.

Where does Samsung Bioepis rank among its competitors?

Samsung Bioepis ranks 3rd amongst 82 active competitors, of which 26 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Rani Therapeutics, which secured $60.3M in Oct, 2025.

Who are the top competitors of Samsung Bioepis?

Samsung Bioepis' top competitors include Protagonist Therapeutics, Shattuck Labs and Auron Therapeutics. Among them, Rani Therapeutics secured the most recent funding round in October, 2025.

Samsung Bioepis - 2026 Company Profile, Funding, Competitors & Financials

Samsung Bioepis is an acquired company based in Incheon (South Korea), founded in 2012. It operates as a Developer of biosimilar drugs for the treatment of multiple diseases. , with last known valuation of $*****. The company has 82 active competitors, including 26 funded and 19 that have exited. Its top competitors include companies like Protagonist Therapeutics, Shattuck Labs and Auron Therapeutics.

Company Details

Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Ontruzant is Samsung Bioepis’ first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.

Website: samsungbioepis.com
Social
Phone Number: +82 **********
Part Of

Key Metrics

Founded Year

2012

Location

Incheon, South Korea

Stage

Acquired

Last Known Valuation

$***** as on Jan 27, 2022

Investors

Biogen & 1 more

Ranked

3^rd among 82 active competitors

Employee Count

1,586 as on Mar 31, 2026

Investment & Acquisitions

C₂N Diagnostics

Similar Companies

Protagonist Therapeutics & 78 more

Exit Details

Acquired by Samsung BioLogics (Jan 27, 2022)

View Samsung Bioepis' full profile

Samsung Bioepis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Samsung Bioepis Co., Ltd CIN: 120111-0601501 , South Korea, Active		$660M (As on Dec 31, 2020)	-	-

Samsung Bioepis got acquired by Samsung BioLogics on Jan 27, 2022 at an acquisition amount of $2.3B. It was facilitated by Moelis & Company.

Click here to take a look at Samsung Bioepis's acquisition in detail

Samsung Bioepis is a funded company. Samsung Bioepis has 2 institutional investors.

View details of Samsung Bioepis's funding rounds and investors

Samsung Bioepis' employee count trend

Samsung Bioepis has 1,586 employees as of Mar 26. Here is Samsung Bioepis's employee count trend over the years:

Employee count trend for Samsung Bioepis

Uncover Samsung Bioepis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Samsung Bioepis include Protagonist Therapeutics, Shattuck Labs and Auron Therapeutics. Here is the list of Top 10 competitors of Samsung Bioepis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Protagonist Therapeutics 2001, Milpitas (United States), Public	Developer of oral peptide therapeutics for gastrointestinal diseases	$67M	Lilly Ventures, Canaan & 12 others	67/100
2nd	Shattuck Labs 2016, Austin (United States), Public	Developer of an immunotherapy platform for oncology and other diseases	$165M	Redmile Group, Orbimed & 13 others	64/100
3rd	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	64/100
4th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Polaris Partners & 11 others	62/100
5th	Alumis 2003, San Francisco (United States), Public	Developer of therapeutics for the treatment of auto-immune disease	$529M	Foresite Capital, VenBio & 13 others	62/100
6th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	E&Investment, Mitsubishi UFJ Capital & 4 others	61/100
7th	Rani Therapeutics 2012, San Jose (United States), Public	Developer of technology for the oral delivery of large drug molecules	$226M	Cathay Financial Holdings, Shire & 18 others	61/100
8th	Aclaris Therapeutics 2012, Malvern (United States), Public	Biopharmaceutical company empowering patients through therapeutic innovation in immuno-inflammatory conditions	$82M	RA Capital Management, F-Prime Capital & 13 others	60/100
9th	Quell 2019, London (United Kingdom), Series B	Developer of T regulatory cell therapies for immunological diseases	$344M	Syncona, Fidelity Investments & 17 others	59/100
10th	Enterome 2008, Paris (France), Series E	Developer of immunomodulatory drugs targeting cancer and immune diseases	$130M	Seventure Partners, Lundbeck Foundation & 10 others	58/100